🎉 M&A multiples are live!
Check it out!

Cyclo Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cyclo Therapeutics and other public comps.

See Cyclo Therapeutics Valuation Multiples

Cyclo Therapeutics Overview

About Cyclo Therapeutics

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.


Founded

1990

HQ

United States of America
Employees

8

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$43.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cyclo Therapeutics Financials

Cyclo Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cyclo Therapeutics achieved revenue of $1.1M and an EBITDA of -$20.0M.

Cyclo Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cyclo Therapeutics valuation multiples based on analyst estimates

Cyclo Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $1.4M $1.1M n/a n/a XXX
Gross Profit $1.4M $1.2M $1.0M XXX XXX
Gross Margin 104% 115% NaN% XXX XXX
EBITDA -$15.6M -$20.0M n/a n/a XXX
EBITDA Margin -1133% -1861% NaN% NaN% XXX
Net Profit -$14.3M -$15.5M -$20.1M XXX XXX
Net Margin -1038% -1435% NaN% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Cyclo Therapeutics Stock Performance

As of February 14, 2025, Cyclo Therapeutics's stock price is $1.

Cyclo Therapeutics has current market cap of $31.9M, and EV of $43.2M.

See Cyclo Therapeutics trading valuation data

Cyclo Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$43.2M $31.9M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cyclo Therapeutics Valuation Multiples

As of February 14, 2025, Cyclo Therapeutics has market cap of $31.9M and EV of $43.2M.

Cyclo Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Cyclo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cyclo Therapeutics and 10K+ public comps

Cyclo Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $43.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cyclo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cyclo Therapeutics Valuation Multiples

Cyclo Therapeutics's NTM/LTM revenue growth is n/a

Cyclo Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $2.6M for the same period.

Over next 12 months, Cyclo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cyclo Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cyclo Therapeutics and other 10K+ public comps

Cyclo Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $2.6M XXX XXX XXX XXX
S&M Expenses to Revenue 0% XXX XXX XXX XXX
G&A Expenses to Revenue 526% XXX XXX XXX XXX
R&D Expenses to Revenue 1318% XXX XXX XXX XXX
Opex to Revenue 1955% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Cyclo Therapeutics Public Comps

See valuation multiples for Cyclo Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cyclo Therapeutics M&A and Investment Activity

Cyclo Therapeutics acquired  XXX companies to date.

Last acquisition by Cyclo Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cyclo Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cyclo Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cyclo Therapeutics

When was Cyclo Therapeutics founded? Cyclo Therapeutics was founded in 1990.
Where is Cyclo Therapeutics headquartered? Cyclo Therapeutics is headquartered in United States of America.
How many employees does Cyclo Therapeutics have? As of today, Cyclo Therapeutics has 8 employees.
Who is the CEO of Cyclo Therapeutics? Cyclo Therapeutics's CEO is Mr. N. Scott Fine.
Is Cyclo Therapeutics publicy listed? Yes, Cyclo Therapeutics is a public company listed on NAS.
What is the stock symbol of Cyclo Therapeutics? Cyclo Therapeutics trades under CYTH ticker.
When did Cyclo Therapeutics go public? Cyclo Therapeutics went public in 2020.
Who are competitors of Cyclo Therapeutics? Similar companies to Cyclo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cyclo Therapeutics? Cyclo Therapeutics's current market cap is $31.9M
Is Cyclo Therapeutics profitable? Yes, Cyclo Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.